probably undervalued by half....

In today's AFR page 24

"It's time to get biotechnical"

a snip


"Chief executive Thomas Liquard says if the trial is a success, the drug HA-Irinotecan could hit sales of at least $400 million and up to $1 billion based on a similar product that is used to treat breast cancer. "We're probably undervalued by half right now," he argues pointing to the US cancer drug developers."

I have a hard copy, so I am not sure if this link is the correct one, although most likely, as most of the same companies discussed.

http://www.afr.com/p/personal_finance/smart_money/how_to_pick_the_next_hot_biotechnology_sm5ohPvRfgmZNwzW1HNYIM